Additional file 4 of Farnesyltransferase inhibitor LNK-754 attenuates axonal dystrophy and reduces amyloid pathology in mice

  • Leah K. Cuddy (Northwestern University) (Creator)
  • Alia O. Alia (Creator)
  • Miranda A. Salvo (Creator)
  • Sidhanth Chandra (Creator)
  • Tom Grammatopoulos (Creator)
  • Craig J. Justman (Creator)
  • Peter T. Lansbury (Creator)
  • Joe Mazzulli (Creator)
  • Robert J Vassar (Creator)
  • Peter T. Lansbury (Creator)



Additional file 4: Supplementary Fig. 4. Effect of LNK-754 and lonafarnib on brain levels of markers of farnesyltransferase inhibition. Immunoblot of brain homogenates from vehicle, LNK-754 and lonafarnib treated 5XFAD mice probed for prelamin-A (A), HDJ-2 (B), phospho-ERK1 (p-P44/P42) and total-P44/P42 (t-P44/P42) (C) and actin. Arrow denotes slower migrating HDJ-2 species in (B). Quantifications of prelamin-A (D) immunoblots in (A), HDJ-2 (*p = 0.036 for vehicle versus LNK-754, *p = 0.023 for LNK-754 versus lonafarnib) (E) immunoblots in (B) (upper band), p-P44/P42 (F) immunoblots in (C). Signals were normalized to actin and expressed as fold of vehicle. Triangles represent males and circles represent females. Vehicle, n = 11 (5 males, 6 females); LNK-754, n = 10 (4 males, 6 females); lonafarnib n = 10 (4 males, 6 females). 1-way ANOVA with Tukey’s post-hoc multiple comparisons test was performed.
Date made available2022

Cite this